Rocket Companies enters the mid-June stretch with short interest at its highest level in at least six weeks — and a fresh analyst downgrade — even as the stock quietly gains ground.
The short-side build that was already the dominant theme in the June 10 note has not paused. SI has climbed to 10.0% of free float, roughly 97 million shares, up nearly 17% over the past week alone and 19% over the past month. The ORTEX short score has tracked this higher, reaching 55.0 — its best reading in the period measured and up from 50.9 a week ago. Yet the lending market continues to offer no punishment for that conviction. Availability is running at 454%, meaning there are more than four shares available to lend for every one currently borrowed, down from 519% when the June 10 note was filed but still firmly in comfortable territory. Cost to borrow has barely moved, sitting at 0.42% — negligible by any measure, and actually lower on the week despite the surge in borrowed shares. Options positioning is equally calm: the put/call ratio is 0.32, fractionally below its 20-day average, and nowhere near the 0.71 reading that marked the 52-week defensive extreme. Shorts are building aggressively, but the borrow market is absorbing the demand without friction, and options traders are not adding incremental hedges.
The Street's direction of travel turned more cautious this week. BTIG downgraded to Neutral from Buy on June 16, removing one of the more constructive ratings in the coverage universe. That leaves the consensus at hold, with five buys against seven holds and a mean price target near $19.60 — still well above the current $13.92, implying meaningful upside on paper. The analyst recommendation differential factor scores in the 94th percentile, a reflection of how many recent moves have been positive in direction, but the BTIG shift chips away at that. Earlier this spring, JPMorgan cut its target sharply from $24 to $16.50, and Wells Fargo trimmed from $19 to $17; both maintained neutral-equivalent ratings. Barclays upgraded to Overweight in April but also cut its target from $22 to $19. The pattern is a Street that sees a recovery story but keeps marking down the multiple at which it's willing to buy it. Valuation multiples tell a similar story: P/E has drifted up to 15.6x on the trailing basis as earnings estimates have been revised, while EV/EBITDA has edged lower to 17.2x over the past 30 days. The EPS momentum factor scores in the 91st percentile on a 30-day basis — a genuine bull-case data point — while the 90-day reading sits at only the 30th percentile, capturing the choppiness in estimate revisions.
The institutional picture adds a mildly interesting wrinkle. BlackRock added 3.6 million shares in its most recent filing, T. Rowe Price added 11.7 million, and Fidelity added 10.1 million — all large-cap managers moving in the same direction. FMR's position of 31.4 million shares is a notable increase from its prior filing. Against that, Slate Path trimmed by 2.5 million and Morgan Stanley cut by 3.3 million. The net institutional flow looks like passive and index-oriented buyers absorbing shares from more active, risk-sensitive sellers. On the insider side, the picture is unremarkable: recent trades have been small, tax-related sells clustered on April 7, and a director's award-and-sell on June 5. Net insider activity for the 90-day window is marginally positive in shares but immaterial in dollar terms.
The most recent earnings print — filed June 10 — produced a 1.9% next-day gain, a muted response compared to the May 7 print that generated a 7.1% pop before fading 2.5% over the subsequent five sessions. The next event is scheduled for July 30. Between now and then, the tension worth watching is whether the ongoing short rebuild — now ten consecutive weeks of higher SI — eventually meets a narrowing of borrow availability, or whether the stock's slow grind higher forces some covering first.
See the live data behind this article on ORTEX.
Open RKT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
